MedPlus Health Services Limited has informed stock exchanges about multiple regulatory actions affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, its subsidiary, has received drug license suspension orders for stores located in Telangana state.

Latest Regulatory Action

The most recent suspension order was issued by the Assistant Director, Drugs Control Administration, Warangal, Telangana, and was received by the company on April 02, 2026. This action specifically targets the store situated at Station Road Jangaon, Telangana.

Previous Regulatory Action

Earlier, the company had received another suspension order for a different store location. The previous action targeted the store at Parkal Main Road, Telangana, with a three-day suspension period and an estimated revenue loss of Rs 0.60 lacs.

Financial Impact Comparison

The company has quantified the potential financial impact of both regulatory actions affecting its subsidiary operations in Telangana.

Compliance Disclosure

The latest disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, in its regulatory filing.

Public Availability

The company stated that the disclosure will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. The filing was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on April 03, 2026.

MedPlus Health Services Limited has announced a board meeting scheduled for May 29, 2026, to consider and approve the company's audited financial results for the fourth quarter and financial year ended March 31, 2026. The announcement was made through a formal communication to stock exchanges on March 28, 2026.

Board Meeting Details

The meeting has been scheduled in compliance with Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will review both standalone and consolidated financial results for the reporting period.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Prevention of Insider Trading, MedPlus Health Services has implemented a trading window closure for designated persons.

Result Publication and Disclosure

Following the board meeting's conclusion, the company will submit the audited financial results to both BSE Limited and National Stock Exchange of India Limited. The results will be made available through multiple channels to ensure comprehensive disclosure to stakeholders.

The financial results will be:

• Submitted to stock exchanges after board meeting conclusion
• Hosted on the company's official website at www.medplusindia.com
• Published in newspapers as per SEBI LODR requirements
• Available on BSE and NSE websites at www.bseindia.com and www.nseindia.com respectively

Regulatory Compliance

The announcement demonstrates MedPlus Health Services' adherence to regulatory requirements and corporate governance standards. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the formal communication, ensuring proper documentation and compliance with listing obligations.